30 Day Trial

CartiHeal Study Enrolls 150th Patient


CartiHeal successfully enrolled the 150th patient in the Investigational Device Exemption clinical study of the Agili-C™ implant. This is an increase from the 100th patient milestone achieved at the beginning of 4Q18.

The objective of the ongoing study is to demonstrate superiority of the cell-free Agili-C implant vs. microfracture and debridement in the treatment of cartilage defects, in both arthritic knees and those without degenerative changes.

A minimum of 250 patients is expected to be enrolled within the next nine to 12 months.

Source: CartiHeal